News

Researching and developing therapies to help patients survive cystic fibrosis (CF) remains one of the main goals of a number of CF research centers and biotech organizations worldwide. However, for the Cystic Fibrosis Lifestyle Foundation, an organization founded in 2003, their goal is to address the…

To find another valuable tool to evaluate the efficacy of the commonly prescribed cystic fibrosis drug ivacaftor (Kalydeco from Vertex Pharmaceuticals), a team from The Ohio State University College of Medicine and Nationwide Children’s Hospital in Columbus, Ohio, tested high resolution computed tomography (HRCT) with cystic fibrosis…

Cystic fibrosis-patient pet owners should have little concern over symptoms from their favorite “Fido,” but those with cuddly “Whiskers” may want to beware. A new study from the Eudowood Division of Pediatric Respiratory Sciences, Institute of Genetic Medicine, and Division of Pediatric Endocrinology in Johns Hopkins, published in…

Xander Bailey is a 18-year-old cystic fibrosis patient who accomplished his dream last weekend thanks to the Make-A-Wish Foundation. The teen was added to the Seattle Sounders soccer team’s lineup and even started a friendly match against Tottenham Hotspur. The Make-A-Wish recipient from Greater Pennsylvania and West Virginia was given…

A proverbial elephant crowding the drug-accessibility room is getting harder and harder to ignore. The high cost of some new pharmaceutical medicines designed to treat devastating and often deadly, but relatively rare disease conditions, combined with concerns over the sustainability of government-led public health systems and current…

A team of researchers from the University of Pittsburgh has discovered that people with unexplained pancreatic problems might have a previously unknown type of cystic fibrosis that doesn’t affect the lungs. According to the Cystic Fibrosis Foundation, there are over 30,000 children and adults in the United…

Two new abstracts from the Journal of Cystic Fibrosis recently focused on the bacteria Pseudomonas aeruginosa (Pa) and sought to enhance knowledge of treating and diagnosing cystic fibrosis. Pa is highly relevant to cystic fibrosis, as it is the most common bacteria in the lungs of patients and leads…

23 year-old Beau Rich is not the first person to plan an inspired cross-country trek across the United States, visiting some of the most picturesque nature spots along the way. He’s also not the first person to plan on filming his travels and putting together a movie about his…

Robert J. Beall, President and CEO of the Cystic Fibrosis Foundation, was invited to a hearing on the theme “21st Century Cures: Incorporating the Patient Perspective,” at the House of Representatives’ Energy and Commerce Committee. The CF Foundation was one of the four patient advocacy institutions selected to testify.

A team of research scientists at the University of Freiburg (Albert-Ludwigs-Universität Freiburg) at Freiburg im Breisgau, Baden-Württemberg, Germany, the University of Geneva, and the University of Grenoble report that they have succeeded in preventing the hospital-acquired bacteria Pseudomonas aeruginosa, a pathogen particularly dangerous to persons with Cystic Fibrosis (CF), from…